Biocon Biologics’ B3 Facility in Bengaluru Gets GMP Nod for Bevacizumab

Biocon

Subsidiary Biocon Biologics’ integrated, multi-product, monoclonal antibodies (mAbs) Drug Substance manufacturing facility (B3) at Biocon Park in Bengaluru, has received a Certificate of GMP Compliance for an additional product, biosimilar Bevacizumab, from the representative European inspection authority, Health Products Regulatory Authority (HPRA), Ireland. Last year B3 facility had received the EU GMP Certification for manufacturing biosimilar.